RxDoctor Payments Data

Deo Samson Perez, PA

Surgical · Tacoma, WANPI 1033305826

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,970 of the $2,393 with a category attached, or 82.3%. Intuitive Surgical accounts for 83.0% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $2,041 and has fallen 87.6% since, to $253 in 2025. Among surgical clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,393in general payments, 2019–2025

Across 22 payments — averaging $108.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$2K
  • Astellas Pharma US Inc$115
  • C. R. Bard, Inc. & Subsidiaries$54
  • Coloplast$49
  • Urogen Pharma, Inc.$36
  • 180 Medical, Inc.$30
  • plus $123 from 6 others

What the payments were for

  • Travel & lodging$1,97082%
  • Food & beverage$41918%
  • Education$40%

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,393 in reported general payments places this provider in the 90th percentile of 404 surgical providers in Washington.

See all surgical providers in Washington

Medicare billing

Part B allowed, 2024
$21,822
Medicare patients
144
Services billed
1,181

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron18$16,065
Tamsulosin Hcl151$2,886
Methenamine Hippurate12$1,563
Solifenacin Succinate24$1,215
Finasteride55$818
Oxybutynin Chloride ErOxybutynin Chloride53$740
Alfuzosin Hcl ErAlfuzosin Hcl17$367
Oxybutynin Chloride20$282
Oxycodone Hcl25$59
Ibuprofen12$39

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$115$16,06518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 404 surgical providers in Washington.

Other surgical in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →